DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.  Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15 billion by 2030.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

The Premier Consulting Blog

APRIL 27, 2023

offers significant advancements in the way that sponsors and regulatory bodies handle submissions, and adapting to these improvements will be mandatory across all major regulatory authorities by 2028 (earlier, in many regions). This blog post gives an overview of the changes that eCTD v4.0 As of April 2023, the FDA is overseeing its eCTD v4.0

Packaging 52

Packaging FDA International Pharmaceuticals 52

DrugBank

SEPTEMBER 26, 2024

The EMA's stringent requirements aim to ensure that biosimilars are as safe and effective as their reference products, thus safeguarding patient health and maintaining the integrity of the pharmaceutical market. billion by 2028. Understanding the financial implications of biosimilars is important for investors and analysts.

Biosimilars 98

Biosimilars Clinical Trials Production FDA 98

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. So it was that this sector was led by the Googles, Amazons, and Metas of the world, whose technological dominance allowed them to extend into pharmaceuticals. The next model of life had officially been released. First, the models targeted the oceans.

Engineering 141

Engineering Virus DNA Therapies 141

The Pharma Data

JANUARY 19, 2021

Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 It hopes to raise about $160 million in aggregate principal amount of 7.375% senior notes due 2025 and $270 million in aggregate principal amount of 7.250% senior notes due 2028. million shares of common stock at $14 per share, to raise $75.6

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. state pharmaceutical assistance programs). Sunsetting of Coverage Gap Discount Program: The 70% coverage gap discount under the CGDP will continue until December 31, 2024. Final Guidance at 2.

Compliance 105

Compliance Drugs Pharmacy Licensing 105

Agency IQ

MARCH 15, 2024

California implements a variety of extended producer responsibility (EPR), programs, including programs to address paint, carpet, mattress, pharmaceutical and battery waste. Improving recycling: SB 54 contains a set of recycling targets that increase between 2028 and 2032. That amount will increase to 40% in 2030 and 65% in 2032.

Regulations 40

Regulations Packaging Compliance Production 40